[go: up one dir, main page]

WO2008033987A3 - Compositions et procédés de prévention du cancer avec des cupredoxines - Google Patents

Compositions et procédés de prévention du cancer avec des cupredoxines Download PDF

Info

Publication number
WO2008033987A3
WO2008033987A3 PCT/US2007/078371 US2007078371W WO2008033987A3 WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3 US 2007078371 W US2007078371 W US 2007078371W WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cupredoxins
tissues
animals
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078371
Other languages
English (en)
Other versions
WO2008033987A2 (fr
Inventor
Gupta Tapas Das
Ananda Chakrabarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002663498A priority Critical patent/CA2663498A1/fr
Priority to BRPI0714987-5A priority patent/BRPI0714987A2/pt
Priority to EP07842403A priority patent/EP2061498A4/fr
Priority to MX2009002787A priority patent/MX2009002787A/es
Priority to AU2007296429A priority patent/AU2007296429A1/en
Priority to JP2009528468A priority patent/JP2010503409A/ja
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of WO2008033987A2 publication Critical patent/WO2008033987A2/fr
Anticipated expiration legal-status Critical
Priority to IL197602A priority patent/IL197602A0/en
Priority to NO20091267A priority patent/NO20091267L/no
Publication of WO2008033987A3 publication Critical patent/WO2008033987A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions constituées de peptides pouvant être des variantes, des dérivés et des équivalents structurels des cupredoxines qui inhibent le développement de lésions prémalignes dans des cellules, des tissus et des animaux mammaliens. De manière spécifique, ces compositions peuvent contenir de l'azurine de Pseudomonas aeruginosa, et/ou la région résiduelle 50-77 de l'azurine (p28). La présente invention concerne en outre des compositions qui peuvent contenir une ou plusieurs cupredoxines, et/ou des variantes, des dérivés ou des équivalents structurels des cupredoxines et peuvent conserver la capacité d'inhiber le développement de lésions prémalignes dans des cellules, des tissus ou des animaux mammaliens. Ces compositions peuvent, entre autres, être des peptides ou des compositions pharmaceutiques. Il est possible d'utiliser les compositions de l'invention pour prévenir le développement de lésions prémalignes dans des cellules, des tissus et des animaux mammaliens, et de ce fait prévenir le cancer.
PCT/US2007/078371 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines Ceased WO2008033987A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0714987-5A BRPI0714987A2 (pt) 2006-09-14 2007-09-13 composiÇÕes e mÉtodos para a prevenÇço do cÂncer com cupredoxina
EP07842403A EP2061498A4 (fr) 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines
MX2009002787A MX2009002787A (es) 2006-09-14 2007-09-13 Composiciones y métodos para prevenir el cáncer con cupredoxinas.
AU2007296429A AU2007296429A1 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins
JP2009528468A JP2010503409A (ja) 2006-09-14 2007-09-13 クプレドキシンによって癌を予防する組成物および方法
CA002663498A CA2663498A1 (fr) 2006-09-14 2007-09-13 Compositions et procedes de prevention du cancer avec des cupredoxines
IL197602A IL197602A0 (en) 2006-09-14 2009-03-15 Compositions and methods to prevent cancer with cupredoxins
NO20091267A NO20091267L (no) 2006-09-14 2009-03-26 Sammensetninger og fremgangsmåter for å forebygge kreft med cupredoxiner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84435806P 2006-09-14 2006-09-14
US60/844,358 2006-09-14

Publications (2)

Publication Number Publication Date
WO2008033987A2 WO2008033987A2 (fr) 2008-03-20
WO2008033987A3 true WO2008033987A3 (fr) 2009-04-30

Family

ID=39184582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078371 Ceased WO2008033987A2 (fr) 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines

Country Status (13)

Country Link
EP (1) EP2061498A4 (fr)
JP (2) JP2010503409A (fr)
KR (1) KR20090059152A (fr)
CN (1) CN101595124A (fr)
AU (1) AU2007296429A1 (fr)
BR (1) BRPI0714987A2 (fr)
CA (1) CA2663498A1 (fr)
IL (1) IL197602A0 (fr)
MX (1) MX2009002787A (fr)
NO (1) NO20091267L (fr)
RU (1) RU2009113812A (fr)
SG (1) SG174784A1 (fr)
WO (1) WO2008033987A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
KR20070108128A (ko) 2004-10-07 2007-11-08 아난다 차크라바르티 쿠프레독신 유래된 수송제 및 이들의 이용 방법
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
BRPI0615562A2 (pt) 2005-07-19 2010-01-26 Univ Illinois agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso
RU2009125599A (ru) 2006-12-04 2011-01-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы лечения рака cpg-богатой днк и купредоксинами
BRPI0806451A2 (pt) * 2007-02-08 2014-07-15 Univ Illinois Composições e métodos para a prevenção do câncer com cupredoxinas
JP7116165B2 (ja) * 2017-09-29 2022-08-09 オンクグノスティクス ゲーエムベーハー 新生物および癌のリスク決定

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
KR20070108128A (ko) * 2004-10-07 2007-11-08 아난다 차크라바르티 쿠프레독신 유래된 수송제 및 이들의 이용 방법
WO2007018671A2 (fr) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions et methodes de traitement d'etats associes a la signalisation de l'ephrine au moyen de cupredoxines
AU2006284490A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARVIDSSON ET AL.: "The azurin gene from Pseudomonas aeruginosa cloning and characterization.", EUR. J. BIOCHEM., vol. 179, 1989, pages 195 - 200, XP008107831 *
YAMADA ET AL.: "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.", PNAS, vol. 99, no. 22, 2002, pages 14098 - 14103, XP002486971 *

Also Published As

Publication number Publication date
WO2008033987A2 (fr) 2008-03-20
BRPI0714987A2 (pt) 2013-07-30
JP2010503409A (ja) 2010-02-04
KR20090059152A (ko) 2009-06-10
MX2009002787A (es) 2009-08-27
EP2061498A4 (fr) 2009-11-04
IL197602A0 (en) 2011-08-01
JP2014050390A (ja) 2014-03-20
RU2009113812A (ru) 2010-10-20
NO20091267L (no) 2009-06-04
CA2663498A1 (fr) 2008-03-20
AU2007296429A1 (en) 2008-03-20
CN101595124A (zh) 2009-12-02
EP2061498A2 (fr) 2009-05-27
SG174784A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
WO2008033987A3 (fr) Compositions et procédés de prévention du cancer avec des cupredoxines
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2008030273A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2007077561A3 (fr) Compositions et procédés permettant d'améliorer le captage in-vivo d'agents pharmaceutiques
WO2008048288A3 (fr) Nouvelles nanoparticules et leur utilisation
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2008133722A3 (fr) Anticorps et diagnostics
WO2007109812A3 (fr) Composes de potentialisation immunitaire
WO2007102149A3 (fr) Dérivés hydrazido de l'acide hyaluronique
MY148496A (en) Dpp iv inhibitor formulations
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2011008495A3 (fr) Formulations d'arginase et procédés
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
WO2007149287A3 (fr) Compositions de facteur de transfert et méthodes
WO2008136865A3 (fr) (s)-n-stéréoisomères d'analogues de 4,5-époxy-morphinanium saturés en 7,8
WO2008117125A3 (fr) Compositions capables de faciliter la pénétration à travers une barrière biologique
WO2007056681A3 (fr) Procedes d'administration d'agents hypoglycemiques
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2009016181A3 (fr) Agents pour l'imagerie optique
WO2006108075A3 (fr) Compositions et methodes accroissant la sensibilite aux medicaments et traitant les infections et maladies presentant une resistance aux medicaments
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041762.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842403

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 575506

Country of ref document: NZ

Ref document number: 2007296429

Country of ref document: AU

Ref document number: 2663498

Country of ref document: CA

Ref document number: 521/MUMNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/002787

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842403

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007296429

Country of ref document: AU

Date of ref document: 20070913

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097007352

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009113812

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714987

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090313